NASDAQ - Precision BioSciences, Inc.

График котировок Precision BioSciences, Inc.

Добавить в список сравнения Добавить в список сравнения
Добавить в список отслеживания Добавить в список отслеживания
Добавить в портфель Добавить в портфель

Основные параметры

P/S 31.5
P/BV 10.12
EBITDA -0.0998
Цена ао 12.3

Все параметры ⇨



Название Значение Оценка
P/S 31.5 1
P/BV 10.12 1
P/E 0
EV/EBITDA -5.83 10


Название Значение Оценка
ROA, % -31.53 1
ROE, % -96.96 1


Название Значение Оценка
Div yield, % 0
DSI 0 0


Название Значение Оценка

Импульс роста

Название Значение Оценка
Рост прибыли, % 0 0
Рост цены акции, % 0 0
Рост дивидендов, % 0 0

Основные владельцы

Institutions Объем Доля, %
Jacob Asset Management Of New York LLC 78000 0.14
CHI Advisors LLC 1014840 1.8
Windmill Hill Asset Management Limited 757891 1.35
Adams Chetwood Wealth Management LLC 240968 0.43
Principal Global Investors, LLC 997878 1.77
First Trust Portfolios L.P. 10174 0.02
venBio Partners LLC 1298191 2.31
Bayview Asset Management Co., Ltd. 98700 0.18
Motif Capital Management, Inc 950 0
Allianz Global Investors U.S. LLC 19154 0.03
BlackRock Fund Advisors 3982306 7.08
Global X Management Company LLC 95122 0.17
Moloney Securities Asset Management 342000 0.61
Integral Health Asset Management, LLC 300000 0.53
SEI Investments Management Corp 260225 0.46
State Street Global Advisors 520610 0.93
Sio Capital Management, LLC 355963 0.63
Allianz Global Investors 30196 0.05
SSGA Funds Management Inc 1826074 3.25
Lyxor International Asset Management S.A.S. 94780 0.17

Содержится в ETF

ETF Доля, % Доходность за год, % Дивиденды, %
Virtus LifeSci Biotech Clinical Trials ETF 0.87 51.04 0.79

Похожие компании

Описание Precision BioSciences, Inc.

Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States. The company operates through two segments, Therapeutic and Food. It offers ARCUS, a genome-editing platform to cure cancers and genetic disorders. The Therapeutic segment develops allogeneic CAR T immunotherapy that recognizes and kills cancer cells; and engages in the in vivo gene correction activities. This segment develops PBCAR0191, which is in Phase 1\u002F2a clinical trial, an allogeneic CAR T cell therapy targeting the tumor target CD19 for acute lymphoblastic leukemia and non-hodgkin lymphoma; and PBCAR20A, an allogeneic anti-CD20 CAR T for the treatment NHL, chronic lymphocytic leukemia, and small lymphocytic lymphoma, as well as developing PBCAR269A, an allogeneic anti-BCMA CAR T cell product candidate for the treatment of R\u002FR multiple myeloma. The Food segment develops food and nutrition products. The company has a development and commercial license agreement with Shire Plc for research and development of individual T cell modifications; and a collaboration agreement with Gilead Sciences, Inc. to co-develop a product candidate to cure chronic Hepatitis B infection. Precision BioSciences, Inc. was founded in 2006 and is headquartered in Durham, North Carolina.